Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell stem cell 2018-06, Vol.22 (6), p.951-959.e3
Hauptverfasser:	Choi, Michael Y., Widhopf, George F., Ghia, Emanuela M., Kidwell, Reilly L., Hasan, Md Kamrul, Yu, Jian, Rassenti, Laura Z., Chen, Liguang, Chen, Yun, Pittman, Emily, Pu, Minya, Messer, Karen, Prussak, Charles E., Castro, Januario E., Jamieson, Catriona, Kipps, Thomas J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - chemistry Antibodies, Monoclonal, Humanized - metabolism Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Dose-Response Relationship, Drug Drug Tolerance Humans Infusions, Intravenous Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - metabolism Leukemia, Lymphocytic, Chronic, B-Cell - pathology Receptor Tyrosine Kinase-like Orphan Receptors - antagonists & inhibitors Receptor Tyrosine Kinase-like Orphan Receptors - genetics Receptor Tyrosine Kinase-like Orphan Receptors - metabolism Signal Transduction - drug effects Signal Transduction - genetics Structure-Activity Relationship
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!